Literature DB >> 18612997

ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis.

Jian Huang1, Yun Lin, Lihua Li, Deng Qing, Xiao-Mei Teng, Yun-Li Zhang, Xin Hu, Yuanjie Hu, Pengyuan Yang, Ze-guang Han.   

Abstract

The identification of cancer genes differentially expressed in hepatocellular carcinoma (HCC) plays an important role in understanding the molecular mechanisms of hepatocarcinogenesis. Here, ARHI gene expression was analyzed by real-time RT-PCR and it was significantly downregulated in 33 of the 42 (78.6%, more than two folds) HCC specimens compared with adjacent noncancerous livers (P < 0.01). In addition, ARHI expression was reduced in some HCC samples at protein level confirmed by immunohistochemistry. Furthermore, our data suggested that the overexpression of ARHI can significantly inhibit cell growth and colony formation of Hep3B cells (P < 0.01), whilst silencing endogenous ARHI gene by RNAi could promote cell growth of Huh-7 and Focus. LOH of microsatellite markers D1S2806 and D1S2803 was only found in 2.4% (1 of 42 HCCs) of HCC cases. The expression of ARHI was obviously re-expressed in some HCC cells, Bel-7402, Bel-7405, QGY-7703 and Hep3B, by a demethylation agent, 5-aza-2'-deoxycytidine (DAC). DNA hypermethylation within ARHI promoter was identified in 47.1% of HCC specimens without ARHI expression. Our current observations provide evidences that ARHI downregulated in HCCs could play a role in liver cancer via acting as a tumor suppressor gene, which mainly was triggered by the epigenetic events in HCC specimens. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18612997     DOI: 10.1002/mc.20461

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  14 in total

1.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Over-expression of ARHI decreases tumor growth, migration, and invasion in human glioma.

Authors:  Jing Chen; Songsheng Shi; Weizhong Yang; Chunmei Chen
Journal:  Med Oncol       Date:  2014-01-24       Impact factor: 3.064

3.  Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes.

Authors:  Jacqueline Brown; Hannelie Bothma; Robin Veale; Pascale Willem
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

4.  Somatic Mutation of ARHI Gene in Hepatocellular Carcinomas.

Authors:  Chang Jae Kim; Jung Woo Shin; Seok Won Jung; Bo Ryung Park; Neung Hwa Park
Journal:  Pathol Oncol Res       Date:  2015-07-05       Impact factor: 3.201

5.  Forced expression of methionine adenosyltransferase 1A in human hepatoma cells suppresses in vivo tumorigenicity in mice.

Authors:  Jiaping Li; Komal Ramani; Zhanfeng Sun; Chishing Zee; Edward G Grant; Heping Yang; Meng Xia; Pilsoo Oh; Kwangsuk Ko; José M Mato; Shelly C Lu
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

6.  Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA.

Authors:  Malwina Niemczyk; Yoko Ito; Joanna Huddleston; Anna Git; Sayeda Abu-Amero; Carlos Caldas; Gudrun E Moore; Lovorka Stojic; Adele Murrell
Journal:  Am J Hum Genet       Date:  2013-07-18       Impact factor: 11.025

Review 7.  DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma.

Authors:  Sumadi Lukman Anwar; Ulrich Lehmann
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

8.  DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters.

Authors:  Margie N Sutton; Zhen Lu; Yao-Cheng Li; Yong Zhou; Tao Huang; Albert S Reger; Amy M Hurwitz; Timothy Palzkill; Craig Logsdon; Xiaowen Liang; Joe W Gray; Xiaolin Nan; John Hancock; Geoffrey M Wahl; Robert C Bast
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423

9.  Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers.

Authors:  Magdalena Bryś; Monika Migdalska-Sęk; Dorota Pastuszak-Lewandoska; Ewa Forma; Karolina Czarnecka; Daria Domańska; Ewa Nawrot; Jacek Wilkosz; Waldemar Różański; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2013-01-04       Impact factor: 3.064

10.  Molecular and clinical studies in 138 Japanese patients with Silver-Russell syndrome.

Authors:  Tomoko Fuke; Seiji Mizuno; Toshiro Nagai; Tomonobu Hasegawa; Reiko Horikawa; Yoko Miyoshi; Koji Muroya; Tatsuro Kondoh; Chikahiko Numakura; Seiji Sato; Kazuhiko Nakabayashi; Chiharu Tayama; Kenichiro Hata; Shinichiro Sano; Keiko Matsubara; Masayo Kagami; Kazuki Yamazawa; Tsutomu Ogata
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.